Sansure Biotech Inc. (“Sansure”), now a listed company in China, established in 2008, is a manufacturer and provider of integrated solutions with independent innovation of molecular diagnostics and genetic technology, which has more than 10-year experience specialized in medical diagnostic reagents, nucleic acid diagnostic instruments, complete laboratory solutions and lab chain services. Sansure is committed to providing the best molecular diagnostic solutions compatible with most detection PCR instruments and laboratory environments based on unique technical platforms such as “global leading magnetic-bead extraction systems”, “one of the simplest and fastest one-step DNA/RNA lysis systems”, automated nucleic acid extraction system, portable molecule workstation (POCT devices), and real-time PCR instruments. Nearly 40% of the company’s employees work in the R&D and technical services departments. The company has more than one hundred different registered products in the world, covering infectious diseases, cancer, maternal and child health, blood screening, emerging infectious diseases prevention and control, chronic disease management, such as viral hepatitis, HPV diagnosis, STDs, respiratory tract infections, etc.
During global COVID-19 pandemic, Sansure Solutions, which is precise, fast, simple, friendly-to-use and high-throughput, has become the main solutions for COVID-19 detection in China and other countries in the world, and has contributed to the world pandemic prevention and control. The full range of integrated solutions includes "Novel coronavirus(2019-nCoV) nucleic acid diagnostic kit + Novel coronavirus(2019-nCoV) antigen test + Novel coronavirus (2019-nCoV) POCT rapid test + Novel coronavirus(2019-nCoV) /Flu A /Flu B triple test + Novel coronavirus(2019-nCoV) mutant B.1.1.7 identification test", which covers the types of mutations that have been frequently reported recently. Sansure Solutions have been widely used in around 160 countries globally, such as in France, UK, Germany, Russia, Ukraine, UAE, Saudi Arabia, Thailand, the Philippines, Brazil, Indonesia and so on. Sansure’s innovative nucleic acid diagnostic solutions have already obtained certificates in over 65 countries, such as NMPA of China, US FDA EUA，ANVISA Brazil etc.. Sansure is one of the companies with the most overseas certifications all over the world.
| Full name | Sansure Biotech Inc |
|---|---|
| Abbreviations | Sansure Biotech |
| Code | 688289 |
| Founded | 2008-04-23 |
| Listing | 2020-08-28 |
| Domicile | Changsha |
| Website | http://www.sansure.com.cn/ |
| dmb@sansure.com.cn | |
| STAR Theme | Biomedicine |
| CSRC Sector | Manufacturing |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 7.01 | 0.11 | - |
| R&D expenditure as a % of operating revenue | 1.74% | 10.66% | 11.76% |
| Operating Revenue | 4,762.96 | 365.39 | 303.45 |
| Net Income | 2,616.60 | 39.48 | 6.76 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 4,762.96 | 365.39 | 303.45 |
| Operating Costs | 1,697.32 | 327.93 | 293.25 |
| Operating Income | 3,086.03 | 47.52 | 11.70 |
| Pretax Income | 3,070.16 | 45.46 | 10.69 |
| Income Tax | 453.56 | 5.98 | 3.93 |
| Net Income | 2,616.60 | 39.48 | 6.76 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 5,082.70 | 437.20 | 359.11 |
| Non-current Assets-Total | 371.67 | 205.26 | 192.93 |
| Total Assets | 5,454.37 | 642.47 | 552.04 |
| Liabilities | |||
| Current Liabilities-Total | 688.69 | 73.36 | 145.18 |
| Non-current Liabilities-Total | 20.26 | 11.63 | 10.58 |
| Total Liabilities | 708.95 | 84.99 | 155.76 |
| Stockholder's Equity | |||
| Share Capital | 2,454.95 | 585.68 | 695.33 |
| Retained Profits | 2,290.48 | -28.20 | -299.04 |
| Total Owners' Equity | 4,745.43 | 557.48 | 396.29 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 2,642.28 | 22.41 | 10.07 |
| Net Cash Flows-Investing | -1,715.96 | -94.60 | 77.52 |
| Net Cash Flows-Financing | 1,609.90 | 44.39 | - |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| 朱雀基金－陕西煤业股份有限公司－陕煤朱雀新经济产业单一资产管理计划 | 2.29 | 6.52 |
| 广发证券股份有限公司－朱雀企业优选股票型证券投资基金 | 1.88 | 5.37 |
| 招商银行股份有限公司－朱雀产业臻选混合型证券投资基金 | 1.75 | 5.00 |
| Haiqing Gao | 0.70 | 2.01 |
| 东方证券股份有限公司－朱雀匠心一年持有期混合型证券投资基金 | 0.63 | 1.79 |
| 平安银行股份有限公司－朱雀企业优胜股票型证券投资基金 | 0.62 | 1.76 |
| Guoling Zhang | 0.45 | 1.28 |
| 中信信托有限责任公司－朱雀9期 | 0.23 | 0.65 |
| 华润深国投信托有限公司－朱雀合伙专项证券投资集合资金信托计划 | 0.22 | 0.63 |
| Mingyue Zheng | 0.22 | 0.62 |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.